Research summary ·
Perioperative Antifibrotic Treatment and Early Postoperative Outcomes in Patients With Idiopathic Pulmonary Fibrosis Undergoing Lung Cancer Surgery: A Systematic Review and Meta-Analysis.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This review looked at antifibrotic drugs around lung cancer surgery. The people had idiopathic pulmonary fibrosis, or IPF. They are at high risk of acute flare-ups of IPF after surgery. Flare-ups carry high mortality. The review searched major databases through August 2025. It pooled retrospective cohort studies. Most studies looked at pirfenidone.
What they found
Antifibrotic use was linked to fewer flare-ups within 30 days. The risk ratio was 0.24. At 90 days it was 0.23. It was also linked to lower death rates. The risk ratio was 0.12 at 30 days. It was 0.13 at 90 days. Checks, including a nationwide database study, supported the link. The effect was weaker in those checks. Evidence for nintedanib came from a small case series.
What it means for patients
The authors say antifibrotic drugs, mainly pirfenidone, were linked to fewer flare-ups and deaths. This included the first 30 days after surgery. They say more prospective studies are needed.
Why it is not certain yet
All the studies were retrospective. Links are not proof of cause. Earlier evidence was limited and mixed. The nintedanib evidence was a small case series. The effect was weaker in sensitivity checks.
Source
Perioperative Antifibrotic Treatment and Early Postoperative Outcomes in Patients With Idiopathic Pulmonary Fibrosis Undergoing Lung Cancer Surgery: A Systematic Review and Meta-Analysis.
PubMed · PMID 42928436We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Idiopathic pulmonary fibrosis publications